AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17507543 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day lymphocyte stimulation test (LST)
Number of subjects: 40
Study 17507543 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON‐TB Gold in‐tube (QFT‐GIT) test
Number of subjects: 40
Study 17507543 — intervention group
Group type: EXPERIMENTAL
Intervention: overnight enzyme‐linked immunospot assay (ELISPOT)
Number of subjects: 40
Study 17507543 — intervention group
Group type: EXPERIMENTAL
Intervention: tuberculin skin test (TST)
Number of subjects: 40
Study 15470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg daily)
Number of subjects: 21
Study 15470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 21
Study 15470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole plus Rifabutin
Number of subjects: 21
Study 15470330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 21
Study 11355317 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 75
Study 11355317 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (30 patients with normal colonic transit time)
Number of subjects: 75
Study 11355317 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (30 patients with prolonged colonic transit time)
Number of subjects: 75
Study 11355317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (normal and prolonged transit time)
Number of subjects: 75
Study 9269803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal manometry feedback
Number of subjects: 26
Study 9269803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter electromyography (EMG) feedback
Number of subjects: 26
Study 8489563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day HR
Number of subjects: 12
Study 8489563 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day HR
Number of subjects: 12
Study 8489563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2881132 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (10(6) IU three times daily for 6 days)
Number of subjects: 69
Study 2881132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 29613942 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication during ECT
Number of subjects: 41
Study 29613942 — intervention group
Group type: EXPERIMENTAL
Intervention: ROPL (Return of Pupillary Response to Light)
Number of subjects: 41
Study 25775494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-supervised functional electrical stimulation-assisted exercise (FES-ET) for 1 hour/day, 5 days/week for 6 weeks
Number of subjects: 0
Study 25775494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-supervised functional electrical stimulation-assisted exercise (FES-ET)
Number of subjects: 0
Study 24096180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination with opt-in orders
Number of subjects: 1264
Study 24096180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination with standing orders
Number of subjects: 1264
Study 24096180 — intervention group
Group type: COMPARATOR
Intervention: Standard practice in comparison hospital
Number of subjects: 1264
Study 24624877 — intervention group
Group type: EXPERIMENTAL
Intervention: ILK siRNA group
Number of subjects: 6
Study 24624877 — intervention group
Group type: EXPERIMENTAL
Intervention: LY294002 group
Number of subjects: 6
Study 24624877 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 6
Study 20204951 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory depletion manipulation
Number of subjects: 0
Study 20204951 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 19463347 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention plus medical therapy (PCI+MT)
Number of subjects: 384
Study 19463347 — intervention group
Group type: COMPARATOR
Intervention: Initial medical therapy only (MT)
Number of subjects: 384
Study 16627442 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral bolus propafenone (600 mg)
Number of subjects: 35
Study 16627442 — intervention group
Group type: EXPERIMENTAL
Intervention: No oral bolus therapy (no bolus)
Number of subjects: 35
Study 16627442 — intervention group
Group type: COMPARATOR
Intervention: Single oral bolus placebo
Number of subjects: 35
Study 14674506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP stored in de‐ionized water (D-W)
Number of subjects: 156
Study 14674506 — intervention group
Group type: COMPARATOR
Intervention: Spectrum TPH stored in silicone fluid (S-O)
Number of subjects: 156
Study 14674506 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrum TPH stored in de‐ionized water (S-W)
Number of subjects: 156
Study 14674506 — intervention group
Group type: COMPARATOR
Intervention: Dyract AP stored in silicone fluid (D-O)
Number of subjects: 156
Study 11184222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group nutrition education (three meetings discussing positive health effects of a Mediterranean diet)
Number of subjects: 0
Study 11184222 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched information based on the Transtheoretical Model of behavior change
Number of subjects: 0
Study 11184222 — intervention group
Group type: COMPARATOR
Intervention: Group nutrition education and stage-matched information
Number of subjects: 0
Study 11184222 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually stage-matched tailored letters
Number of subjects: 0
Study 8790131 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured encounter forms focused on developmental milestones (group 1)
Number of subjects: 206
Study 8790131 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured encounter forms focused on anticipatory guidance/preventive care (group 2)
Number of subjects: 206
Study 8434380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 113
Study 8434380 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without diltiazem (ND)
Number of subjects: 113
Study 3319120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel)
Number of subjects: 51
Study 3319120 — intervention group
Group type: COMPARATOR
Intervention: L‐DOPA/carbidopa (Sinemet)
Number of subjects: 51
Study 30017536 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 96
Study 27373874 — intervention group
Group type: EXPERIMENTAL
Intervention: 163 kcal (very low energy meal, VLEM)
Number of subjects: 27
Study 27373874 — intervention group
Group type: EXPERIMENTAL
Intervention: 302 kcal (low energy meal, LEM)
Number of subjects: 27
Study 27373874 — intervention group
Group type: COMPARATOR
Intervention: 605 kcal (control)
Number of subjects: 27
Study 27373874 — intervention group
Group type: EXPERIMENTAL
Intervention: 889 kcal (high energy meal, HEM)
Number of subjects: 27
Study 27373874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1176 kcal (very high energy meal, VHEM)
Number of subjects: 27
Study 25117895 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Mothers and Schools (PMAS) initiative - group parenting time, life skills, and leadership training
Number of subjects: 115
Study 25117895 — intervention group
Group type: COMPARATOR
Intervention: Control group - homebound education and family case management
Number of subjects: 115
Study 23153177 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide added to insulin therapy
Number of subjects: 84
Study 23153177 — intervention group
Group type: COMPARATOR
Intervention: Insulin dose-increase
Number of subjects: 84
Study 18729731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined folic acid and B-vitamin therapy
Number of subjects: 0
Study 18729731 — intervention group
Group type: COMPARATOR
Intervention: Vitamin therapy
Number of subjects: 0
Study 17724646 — intervention group
Group type: EXPERIMENTAL
Intervention: DIGITOS-prosthesis
Number of subjects: 16
Study 15842827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Number of subjects: 86
Study 15842827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 86
Study 15842827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dimercaptopropane sulfonate
Number of subjects: 86
Study 15842827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 12518724 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with antioxidants (vitamin E 200 mg/d and polyunsaturated fatty acids 1,000 mg/d)
Number of subjects: 35
Study 12518724 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy only (no antioxidants)
Number of subjects: 35
Study 12518724 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with antioxidants
Number of subjects: 35
Study 12518724 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy only
Number of subjects: 35
Study 10097446 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteometric dimensions of metacarpal bones (length, total diaphysis width, medullary canal width)
Number of subjects: 173
Study 8172090 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d fiber supplement
Number of subjects: 127
Study 8172090 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/d fiber supplement
Number of subjects: 127
Study 8172090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 29243270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (mean BAC = 0.07%)
Number of subjects: 79
Study 29243270 — intervention group
Group type: COMPARATOR
Intervention: Tonic water (control group)
Number of subjects: 79
Study 29243270 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief of having consumed alcohol
Number of subjects: 79
Study 29243270 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-blame levels
Number of subjects: 79
Study 27344348 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week table tennis exercise (group I)
Number of subjects: 32
Study 27344348 — intervention group
Group type: COMPARATOR
Intervention: 12-week table tennis exercise (group II)
Number of subjects: 32
Study 25790451 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-L6 intervention (increasing omega-3 fatty acids and reducing omega-6 linoleic acid)
Number of subjects: 67
Study 25790451 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-L6 intervention
Number of subjects: 67
Study 25790451 — intervention group
Group type: COMPARATOR
Intervention: L6 intervention (omega-6 lowering)
Number of subjects: 67
Study 23924679 — intervention group
Group type: COMPARATOR
Intervention: 4 × 25-mg non-coated tablets
Number of subjects: 110
Study 23924679 — intervention group
Group type: COMPARATOR
Intervention: 100-mg tablet dispersed in 100 ml water
Number of subjects: 110
Study 23924679 — intervention group
Group type: COMPARATOR
Intervention: 200-mg non-coated and coated tablets
Number of subjects: 110
Study 23924679 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg tablets
Number of subjects: 110
Study 23924679 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg tablets
Number of subjects: 110
Study 20334748 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 167
Study 20334748 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist outpatient treatment
Number of subjects: 167
Study 20334748 — intervention group
Group type: COMPARATOR
Intervention: General CAMHS treatment
Number of subjects: 167
Study 20334748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 167
Study 20334748 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction measures
Number of subjects: 167
Study 18990973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program (INTERCOM trial)
Number of subjects: 127
Study 16487836 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14703
Study 16487836 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14703
Study 16487836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and valsartan
Number of subjects: 14703
Study 14607306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 100
Study 14607306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10767065 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional contrast-enhanced moving-bed infusion-tracking (MoBI-track) peripheral MR angiography
Number of subjects: 7
Study 8963977 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental field test (FT) using adapted Léger and Boucher test (ALBT)
Number of subjects: 9
Study 8963977 — intervention group
Group type: COMPARATOR
Intervention: Laboratory test (LT) on adapted treadmill
Number of subjects: 9
Study 1737593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurement
Number of subjects: 200
Study 1737593 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic measurement
Number of subjects: 200
Study 1737593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 200
Study 1737593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical and mammographic measurements
Number of subjects: 200
Study 6378516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment at home (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Number of subjects: 53
Study 6378516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment in hospital (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Number of subjects: 53
Study 6378516 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 53
Study 31322344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-boiling but less-coordinating solvents (DMF) during coordination of dqp by [Ru(dqp)(MeCN)3]2+
Number of subjects: 0
Study 31322344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-boiling but less-coordinating solvents (DMF)
Number of subjects: 0
Study 31322344 — intervention group
Group type: EXPERIMENTAL
Intervention: [Ru(dqp)(MeCN)3]2+
Number of subjects: 0
Study 31322344 — intervention group
Group type: COMPARATOR
Intervention: tpy
Number of subjects: 0
Study 29073780 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI with ropivacaine 2 mg/mL at a rate of 2 mL/h for 24 hours
Number of subjects: 50
Study 29073780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29073780 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI with ropivacaine
Number of subjects: 50
Study 26111491 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing wheal technique
Number of subjects: 29
Study 26111491 — intervention group
Group type: COMPARATOR
Intervention: Gale technique
Number of subjects: 29
Study 24566756 — intervention group
Group type: EXPERIMENTAL
Intervention: beractant
Number of subjects: 92
Study 24566756 — intervention group
Group type: EXPERIMENTAL
Intervention: poractant alfa
Number of subjects: 92
Study 23012417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic reconfiguration of brain network during task preparation
Number of subjects: 0
Study 23012417 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-relevant visual areas
Number of subjects: 0
Study 20974610 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg/day
Number of subjects: 42
Study 20974610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17949466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (low dose 7 mg)
Number of subjects: 55
Study 17949466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (high dose 14 or 21 mg)
Number of subjects: 55
Study 17949466 — intervention group
Group type: COMPARATOR
Intervention: Control (community controls)
Number of subjects: 55
Study 16236688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg/day
Number of subjects: 12
Study 16236688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12487895 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling group (22 patients)
Number of subjects: 41
Study 12487895 — intervention group
Group type: COMPARATOR
Intervention: Non-ILM peeling group (19 patients)
Number of subjects: 41
Study 10425951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10 mg p.o.)
Number of subjects: 66
Study 10425951 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen codeine (325 mg/15 mg p.o.)
Number of subjects: 66
Study 7498204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg.day‐1 in twice divided doses)
Number of subjects: 12
Study 7498204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2405720 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetrahydroaminoacridine (THA) and lecithin
Number of subjects: 10
Study 2405720 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with THA and lecithin
Number of subjects: 10
Study 7026336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 12
Study 7026336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31821591 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod 5 mg/kg
Number of subjects: 38
Study 31821591 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod 10 mg/kg
Number of subjects: 38
Study 31821591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30782756 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant depressive symptoms (score of ≥6 on the Geriatric Depression Scale-15)
Number of subjects: 990
Study 28002363 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level cervical total disc replacement (CTDR)
Number of subjects: 34
Study 28002363 — intervention group
Group type: COMPARATOR
Intervention: Single-level anterior cervical discectomy and fusion (ACDF)
Number of subjects: 34
Study 25849523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention (14-week program with ten 90-minute group sessions and four individual telephone sessions)
Number of subjects: 86
Study 25849523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention
Number of subjects: 86
Study 25849523 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 86
Study 24008684 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based preparation for inpatient psychosomatic psychotherapeutic treatment (VORSTAT)
Number of subjects: 176
Study 21458107 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg
Number of subjects: 55
Study 21458107 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) 3 mg/kg
Number of subjects: 55
Study 19381612 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach (SV)
Number of subjects: 104
Study 19381612 — intervention group
Group type: COMPARATOR
Intervention: Conventional parapatellar approach
Number of subjects: 104
Study 16719647 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar-appearing features
Number of subjects: 0
Study 16719647 — intervention group
Group type: COMPARATOR
Intervention: Novel-appearing features
Number of subjects: 0
Study 14732872 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP gene mutation (L296Q) carriers
Number of subjects: 203
Study 14732872 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (controls)
Number of subjects: 203
Study 11054648 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (80 microg/kg body weight, daily two s.c. injections for five days)
Number of subjects: 15
Study 11054648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injections)
Number of subjects: 15
Study 11054648 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 15
Study 9113634 — intervention group
Group type: EXPERIMENTAL
Intervention: HI20:4 diet (1.7 g/d arachidonic acid)
Number of subjects: 4
Study 9113634 — intervention group
Group type: COMPARATOR
Intervention: LO20:4 diet (0.21 g/d arachidonic acid)
Number of subjects: 4
Study 9113634 — intervention group
Group type: EXPERIMENTAL
Intervention: HI20:4 diet
Number of subjects: 4
Study 9113634 — intervention group
Group type: COMPARATOR
Intervention: LO20:4 diet
Number of subjects: 4
Study 9113634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 4
Study 8453254 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 21
Study 8453254 — intervention group
Group type: COMPARATOR
Intervention: Iodine-free formula-fed infants
Number of subjects: 21
Study 8453254 — intervention group
Group type: COMPARATOR
Intervention: Iodine-supplemented formula-fed infants
Number of subjects: 21
Study 8453254 — intervention group
Group type: COMPARATOR
Intervention: Partially breast-fed infants
Number of subjects: 21
Study 3532439 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride 10 mg intravenously every 12 hours for seven days
Number of subjects: 49
Study 3532439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3532439 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride
Number of subjects: 49
Study 30500094 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant overdenture (IOD)
Number of subjects: 32
Study 30500094 — intervention group
Group type: COMPARATOR
Intervention: Conventional reline of mandibular complete removable dental prostheses (CRDPs)
Number of subjects: 32
Study 28426476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasphincteric injections of autologous myoblasts (AM)
Number of subjects: 24
Study 28426476 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 24
Study 28426476 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed frozen AM injection in placebo group
Number of subjects: 24
Study 26968807 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 120
Study 26968807 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Number of subjects: 120
Study 26968807 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 120
Study 24701571 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine
Number of subjects: 60